Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: Results from a phase 3, randomised, double-blind withdrawal trial

Hermine I. Brunner, Nicolino Ruperto, Zbigniew Zuber, Caroline Keane, Olivier Harari, Andrew Kenwright, Peng Lu, Ruben Cuttica, Vladimir Keltsev, Ricardo M. Xavier, Inmaculada Calvo, Irina Nikishina, Nadina Rubio-Pérez, Ekaterina Alexeeva, Vyacheslav Chasnyk, Gerd Horneff, Violetta Opoka-Winiarska, Pierre Quartier, Clovis A. Silva, Earl SilvermanAlberto Spindler, Eileen Baildam, M. Luz Gámir, Alan Martin, Christoph Rietschel, Daniel Siri, Elzbieta Smolewska, Daniel Lovell, Alberto Martini, Fabrizio De Benedetti, T. Sherrard, A. Johnson, A. Merritt, W. Long, Simona Angioloni, Laura Carenini, Chiara Pallotti, Eugenia Mosci, Marco Garrone, Irene Gregorini, Silvia Scala, Luca Villa, Giuseppe Silvestri, Graciela Espada, Roger Allen, Jeffrey Chaitow, Rik Joos, Carine Wouters, Sheila Knupp, Flavio Sztajnbok, David Cabral, Kristin Houghton, Johannes Roth, Heinrike Schmeling, Chantal Job-Deslandre, Christian Jorgensen, Isabelle Konepaut, Kirsten Minden, Frank Weller, Valeria Gerloni, Francesco Zulian, Ruben Burgos-Vargas, Carolina Duarte Salazar, Eunice Solis Vallejo, Armando Calvo, José Chavez, Manuel Ferrandiz Zavaler, Anna Gruenpeter, Katarzyna Kobusinska, Alexey Sarychev, Elena Zholobova, Athimalaipet Ramanan, Patricia Woo, Abraham Gedalia, Steven Goodman, Yukiko Kimura, Karen Onel, Kenneth Schikler

Research output: Contribution to journalArticle

Abstract

Objective To evaluate the interleukin-6 receptor inhibitor tocilizumab for the treatment of patients with polyarticular-course juvenile idiopathic arthritis ( pcJIA). Methods This three-part, randomised, placebocontrolled, double-blind withdrawal study (NCT00988221) included patients who had active pcJIA for ≥6 months and inadequate responses to methotrexate. During part 1, patients received open-label tocilizumab every 4 weeks (8 or 10 mg/kg for body weight (BW)

Original languageEnglish
Pages (from-to)1110-1117
Number of pages8
JournalAnnals of the Rheumatic Diseases
Volume74
Issue number6
DOIs
Publication statusPublished - Jun 1 2015

    Fingerprint

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Allergy

Cite this

Brunner, H. I., Ruperto, N., Zuber, Z., Keane, C., Harari, O., Kenwright, A., Lu, P., Cuttica, R., Keltsev, V., Xavier, R. M., Calvo, I., Nikishina, I., Rubio-Pérez, N., Alexeeva, E., Chasnyk, V., Horneff, G., Opoka-Winiarska, V., Quartier, P., Silva, C. A., ... Schikler, K. (2015). Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: Results from a phase 3, randomised, double-blind withdrawal trial. Annals of the Rheumatic Diseases, 74(6), 1110-1117. https://doi.org/10.1136/annrheumdis-2014-205351